Update on multiple sclerosis

Jack H Simon1

  • 1Department of Radiology, University of Colorado Health Sciences Center, Denver, CO 80262, USA. jack.simon@uchsc.edu

Insights

Magnetic Resonance Imaging (MRI) reveals focal and diffuse brain lesions in multiple sclerosis (MS). MRI aids in diagnosis, monitoring disease progression, and evaluating treatment effectiveness in MS patients.

Area of Science:

  • Neurology
  • Radiology
  • Neuroimaging

Background:

  • Multiple Sclerosis (MS) is a chronic neurological disease characterized by inflammation and demyelination in the central nervous system.
  • Understanding the pathological features of MS is crucial for accurate diagnosis and effective management.
  • Magnetic Resonance Imaging (MRI) has become an indispensable tool in the study and clinical evaluation of MS.

Purpose of the Study:

  • To review the fundamental features of focal lesions and underlying pathology in MS using MRI.
  • To discuss diffuse pathology in normal-appearing white and gray matter revealed by conventional and quantitative MRI techniques.
  • To explore the role of MRI in diagnosing MS, monitoring subclinical disease, and assessing treatment response.

Main Methods:

  • Review of existing literature on MR imaging findings in multiple sclerosis.
  • Discussion of conventional and quantitative MRI techniques for detecting focal and diffuse brain pathology.
  • Analysis of MR imaging criteria integrated into formal clinical diagnostic criteria for MS.

Main Results:

  • Focal lesions and underlying pathologies in MS are characterized by specific MR imaging features.
  • Diffuse pathology in normal-appearing white and gray matter can be detected using advanced MRI techniques.
  • Axonal-neuronal degeneration may link focal and diffuse pathologies in MS.
  • Established MR imaging criteria are now part of formal clinical diagnostic criteria for MS.

Conclusions:

  • MRI is essential for characterizing both focal and diffuse pathologies in multiple sclerosis.
  • MRI plays a critical role in the diagnostic criteria for MS.
  • MRI is valuable for monitoring subclinical disease activity, identifying aggressive disease, and tracking treatment efficacy in MS.

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...